MAP2K7 and neoplasm: Studies have shown that MEK inhibition (MEKi) enhances the antitumor capacity of patients and can immunomodulate tumor cells and tumor‐infiltrating lymphocytes (TILs), and studies have utilized the CRISPR/Cas system‐mediated MEK1 KO to mimic tumor‐specific MEKi, and pharmacological MEKi using cobimetinib in colorectal cancer models, thereby distinguishing MEKi mediated and dependent mechanisms of immunomodulation.